eFFECTOR Therapeutics, Inc.

LifeSci Acquisition 2 Corp (Nasdaq: LWAC), sponsored by LifeSci SPAC Sponsor 2 LLC, an affiliate of LifeSci Capital, completed its initial public offering in January 2021 with a focus on the healthcare and life sciences sector. The blank-check company subsequently announced and closed a business combination with eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapeutics that target translation regulation — specifically the eIF4F complex — in oncology. The June 2021 10-Q filing under the LWAC ticker reflects reporting activity tied to the de-SPAC transaction period, with eFFECTOR operating as the surviving entity following the merger. Sign up on SpacDesk for full filings, deal timelines, and analytics on LWAC and every active SPAC in the market.